Bicara Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Bicara Therapeutics Inc. (BCAX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Bicara Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.24M, a 135.91% increase year-over-year.
- Bicara Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.86M, a 69.75% increase year-over-year.
- Bicara Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.61M, a 77.94% increase year-over-year.
- Bicara Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.49M, a 236.42% increase year-over-year.
- Bicara Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $15.01M, a 102.87% increase from fiscal 2024.
- Bicara Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $7.40M, a 289.52% increase from fiscal 2023.
- Bicara Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.90M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.24M 10-Q · filed 2026-08-11 | $14.10M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $5.86M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $15.01M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $3.61M 10-Q · filed 2025-11-10 | $7.11M derived: sum of 2 quarters · filed 2026-08-11 | $10.56M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $3.49M 10-Q · filed 2026-08-11 | $6.94M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $3.45M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $7.40M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $2.03M 10-Q · filed 2025-11-10 | $3.07M derived: sum of 2 quarters · filed 2025-11-10 | $4.22M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $1.04M 10-Q · filed 2025-11-10 | $2.19M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $1.15M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $1.90M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $519.00K 10-Q · filed 2024-11-12 | $871.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.14M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $352.00K 10-Q · filed 2024-11-12 | $616.00K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $264.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |